Is visceral adiposity the "enemy within"?
暂无分享,去创建一个
[1] P. Sakkinen,et al. Interleukin-6 exacerbates early atherosclerosis in mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[2] S. Gregory,et al. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin , 1989, Molecular and cellular biology.
[3] S. Coppack,et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[4] L. Kuller,et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[5] T. Strandberg,et al. Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.
[6] W. Koenig,et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.
[7] J. Manson,et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.
[8] Ridker Pm. Novel risk factors and markers for coronary disease. , 2000 .
[9] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[10] N Rifai,et al. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. , 2001, Clinical chemistry.
[11] D. Loskutoff,et al. The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[12] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[13] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[14] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[15] D. Strachan,et al. C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.
[16] S. Haffner,et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.
[17] E. Barrett-Connor,et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.
[18] J. Després,et al. Elevated C-Reactive Protein: Another Component of the Atherothrombotic Profile of Abdominal Obesity , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[19] E. Poehlman,et al. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. , 1999, Diabetes.
[20] R. Puri,et al. Human Cytokines: Their Role in Disease and Therapy , 1995 .
[21] Gerardo Heiss,et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.
[22] E. Poehlman,et al. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 48: 2210-2214 , 1999 .
[23] L. Heilbronn,et al. Energy Restriction and Weight Loss on Very-Low-Fat Diets Reduce C-Reactive Protein Concentrations in Obese, Healthy Women , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[24] R Peto,et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.
[25] R. Tracy,et al. Inflammation markers and coronary heart disease. , 1999, Current opinion in lipidology.
[26] R. Tracy,et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.
[27] R. Virchow,et al. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre , 1861 .
[28] L. Kuller,et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[29] J S Yudkin,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .
[30] S. O’Rahilly,et al. The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.
[31] B. Horne,et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. , 2000, Journal of the American College of Cardiology.
[32] C. Esmon,et al. Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.
[33] J. Kolls,et al. An in Vivo Model for Elucidation of the Mechanism of Tumor Necrosis Factor-α (TNF-α)-Induced Insulin Resistance: Evidence for Differential Regulation of Insulin Signaling by TNF-α. , 1998, Endocrinology.
[34] S Hulley,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[35] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.
[36] R. Tracy. Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.
[37] G. Montalescot,et al. Fibrinogen as a risk factor for coronary heart disease. , 1998, European heart journal.
[38] J. Polak,et al. Association between physical activity and markers of inflammation in a healthy elderly population. , 2001, American journal of epidemiology.
[39] P. Ridker,et al. Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.
[40] J. Verheijen,et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.
[41] J. Yudkin. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? , 1999, Diabetes Care.